4.7 Article

Mechanisms of NMDA receptor inhibition by nafamostat, gabexate and furamidine

Journal

EUROPEAN JOURNAL OF PHARMACOLOGY
Volume 919, Issue -, Pages -

Publisher

ELSEVIER
DOI: 10.1016/j.ejphar.2022.174795

Keywords

NMDA receptors; Pharmacological modulation; Patch clamp; Nafamostat; Gabexate; Furamidine

Ask authors/readers for more resources

In this study, the effects of several drugs on native NMDA receptors in rat hippocampal pyramidal neurons were investigated. It was found that nafamostat, furamidine, and gabexate were able to inhibit the activity of NMDA receptors, while camostat was ineffective. Nafamostat and furamidine showed voltage-dependent inhibition, while gabexate showed voltage-independent inhibition. Nafamostat and furamidine demonstrated a 'foot-in-the-door' mechanism of action. Furamidine, nafamostat, and gabexate have structural similarities to the previously studied diminazene.
N-methyl-D-aspartate (NMDA) receptors are affected by many pharmaceuticals. In this work, we studied the action of the serine protease inhibitors nafamostat, gabexate and camostat, and an antiprotozoal compound, furamidine, on native NMDA receptors in rat hippocampal pyramidal neurons. Nafamostat, furamidine and gabexate inhibited these receptors with IC50 values of 0.20 +/- 0.04, 0.64 +/- 0.13 and 16 +/- 3 mu M, respectively, whereas camostat was ineffective. Nafamostat and furamidine showed voltage-dependent inhibition, while gabexate showed practically voltage-independent inhibition. Nafamostat and furamidine demonstrated tail currents, implying a 'foot-in-the-door' mechanism of action; gabexate did not demonstrate any signs of 'foot-inthe-door' or trapping channel block. Gabexate action was also not competitive, suggesting allosteric inhibition of NMDA receptors. Furamidine and nafamostat are structurally similar to the previously studied diminazene and all three demonstrated a 'foot-in-the-door' mechanism. They have a rather rigid, elongated structures and cannot fold into more compact forms. By contrast, the gabexate molecule can fold, but its folded structure differs drastically from that of typical NMDA receptor blockers, in agreement with its voltage-independent inhibition. These findings provide a better understanding of the structural determinants of NMDA receptor antagonism, while also supporting the potential clinical repurposing of these drugs as neuroprotectors for glaucoma and other neurodegenerative diseases.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available